Chengdu Kanghua Biological Products Co., Ltd. (300841)

Overview

Chengdu Kanghua Biological Products Co., Ltd. is a prominent entity in the biopharmaceutical industry within China, focusing on the domains of research, development, manufacturing, sales, and technical services of various biological products. Since its inception in 2004, the company has positioned itself as a key player in the healthcare and medical sectors, leveraging its capabilities to meet the growing demand for vaccines and other biological products. Based in Chengdu, China, Chengdu Kanghua Biological Products Co., Ltd. not only serves the domestic market but also reaches international clients through its export activities.

Products and Services

• Group ACYW135 Meningococcal Polysaccharide Vaccines

  These are vaccines designed to provide protection against meningococcal disease caused by four serogroups (A, C, W135, and Y) of Neisseria meningitidis. The use of these vaccines is a critical component in the prevention of meningitis and septicemia outbreaks.

• Freeze-Dried Human Diploid Cell Rabies Vaccines

  This vaccine is administered for the prevention of rabies, a deadly virus transmitted through the bites of infected animals. Chengdu Kanghua's version is freeze-dried, which enhances its stability and shelf-life, making it easier to distribute and administer in various settings.

• Seasonal Influenza Vaccines Without Preservatives

  The company has developed influenza vaccines that do not contain preservatives, aiming to reduce the risk of allergic reactions and other side effects. These vaccines, which have successfully completed phase III clinical trials, are formulated to protect against common strains of the flu virus circulating each season.